ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancer

Zhang, Shi-Ling; Zhang, Chan -Yuan; Chen, Yu-Qing; Li, Yu -Fa; Xie, Zhi; Zhang, Xu-Chao; Zhou, Qing; Zhong, Wen-Zhao; Huang, Jie; Sun, Hao; Zheng, Ming-Ying; Xiao, Fa-Man; Yan, Hong-Hong; Lu, Dan-Xia; Lv, Zhi-Yi; Wu, Yi-Long; Chen, Hua-Jun*; Yang, Jin-Ji*广东省人民医院; 南方医科大学
Journal of Thoracic Disease2023-9DOI: 10.21037/jtd-23-161
6阅读
引用收藏
分享

摘要

Background: The transformation of epidermal growth factor receptor (EGFR )-mutant lung adenocarcinoma (LUAD) into small cell lung cancer (SCLC) accounts for 3-14% of the resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs). At present, there is no relevant research to explore the dynamic expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed SCLC/neuroendocrine carcinoma (NEC). Methods: Genetic analysis and protein level analysis by next-generation sequencing (NGS), Wholeexome sequencing (WES) and immunohistochemistry were performed to explore expression of EGFRmutant proteins and genomic evolution in EGFR-mutant transformed SCLC. The research used three patient-derived organoids (PDOs) to explore the efficacy of combo [chemotherapy (chemo) plus TKI or bevacizumab] treatment. According to the subsequent treatment regimens after SCLC/NEC transformation, 35 patients were divided into chemo (n=21) and combo (n=14) groups. Results: EGFR L858R and EGFR E746-750 del protein expression by immunohistochemistry was 80.0% (4/5) and 100% (6/6), respectively (P=0.455) in initially-transformed tissues. Meanwhile, EGFR-mutant proteins were expressed in 85.7% (6/7) of dynamic rebiopsy tissues or effusion samples after the first transformation. Then, by the pathway enrichment analysis of tissue and plasma NGS, the EGFR-related pathways were still activated after SCLC/NEC transformation. Moreover, WES analysis revealed that transformed SCLC shared a common clonal origin from the baseline LUAD. The drug sensitivity of three PDOs demonstrated potent anti-cancer activity of EGFR-TKIs plus chemo, compared with chemo or TKI alone. There were significant differences in objective response rate (ORR) between the combo and chemo groups [42.9 % vs. 4.8%, P=0.010, 95% confidence interval (CI): 1.5-145.2]. Furthermore, the median posttransformation progression-free survival (pPFS) was significantly prolonged in the combo group, with 5.4 Conclusions: EGFR 19del or L858R-mutant proteins could be constantly expressed, and EGFR pathway still existed in EGFR-mutant transformed SCLC/NEC with a common clonal origin from the baseline LUAD. Taking together, these molecular characteristics potentially favored clinical efficacy in transformed SCLC/NEC treated with the combo regimen.

学科与关键词

关键词
Epidermal growth factor receptor-mutant proteins (EGFR-mutant proteins)genomic evolutionresistancesmall cell lung cancer (SCLC)histologic transformation
相关
加载中…
  • A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival
    Zhang, Chan-Yuan; Sun, Hao; Su, Jun-Wei; Chen, Yu-Qing; Zhang, Shi-Ling; Zheng, Ming-Ying; Li, Yu-Fa; Huang, Jie; Zhang, Chao; Tai, Zai-Xian; Cai, Miao; Zhang, Xu-Chao; Su, Jian; Xu, Chong-Rui; Yan, Hong-Hong; Chen, Hua-Jun; Wu, Yi-Long*; Yang, Jin-Ji*Lung Cancer, 2023, 175: 68-78.被引 6
  • Case report: EGFR-mutant lung adenocarcinoma with the TP53 and RB1 mutations showed resistance to TKI therapy
    Lu, Yiyu; Li, Zhihua; Zhu, Huawei; Zhao, Juan; Xu, Mian; Gu, Weiguang*Annals of Palliative Medicine, 2021, 10(12): 12886-12893.被引 1
  • Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
    Zhang, C.; Zhang, S.; Yao, Y.; Gao, Y.; Huang, J.; Peng, K.; Gao, Q.; Chen, H.; Xu, C.; Zhang, X.; Wu, Y.; Yang, J.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Thoracic Disease
发表日期
2023-09
卷期
第 15 卷, 第 9 期
DOI
10.21037/jtd-23-161
语言
ENGLISH
成果收录
SCIE
资助标注
High-Level Hospital Construction Project [DFJH201809]; National Natural Science Foundation of China [81972164]; Natural Science Foundation of Guangdong Province [2019A1515010931]; Key Lab System Project of Guangdong Science and Technology Department -Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]

作者

  • Z

    Zhang, Shi-Ling (第一作者)

    guangdong prov peoples hosp · southern med univ · 2

  • Z

    Zhang, Chan -Yuan

    guangdong prov peoples hosp · southern med univ · 2

查看全部 18 位作者收起作者
  • C

    Chen, Yu-Qing

    2 · guangdong prov peoples hosp

  • L

    Li, Yu -Fa

    guangdong prov peoples hosp

  • X

    Xie, Zhi

    2 · guangdong prov peoples hosp

  • Z

    Zhang, Xu-Chao

    2 · guangdong prov peoples hosp

  • Z

    Zhou, Qing

    2 · guangdong prov peoples hosp

  • Z

    Zhong, Wen-Zhao

    2 · guangdong prov peoples hosp

  • H

    Huang, Jie

    2 · guangdong prov peoples hosp

  • S

    Sun, Hao

    2 · guangdong prov peoples hosp

  • Z

    Zheng, Ming-Ying

    2 · guangdong prov peoples hosp

  • X

    Xiao, Fa-Man

    2 · guangdong prov peoples hosp

  • Y

    Yan, Hong-Hong

    2 · guangdong prov peoples hosp

  • L

    Lu, Dan-Xia

    2 · guangdong prov peoples hosp

  • L

    Lv, Zhi-Yi

    2 · guangdong prov peoples hosp

  • W

    Wu, Yi-Long

    2 · guangdong prov peoples hosp

  • C

    Chen, Hua-Jun (通讯)

    2 · guangdong prov peoples hosp

  • Y

    Yang, Jin-Ji (通讯)

    guangdong prov peoples hosp · southern med univ · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417